{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Overall Survival (OS) was defined as the time from registration to death of any cause. Participants were followed for a maximum of 2 years from registration. The median OS with 95%CI was estimated using the Kaplan Meier method","groups":[{"id":"OG000","title":"Sorafenib + Lenalidomide + Dexamethasone"}],"populationDescription":"No participants proceeded to Phase II for evaluation.","reportingStatus":"POSTED","timeFrame":"From registration to death (up to 3 years)","title":"Overall Survival (Phase II)","type":"SECONDARY"}